A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
Withdrawn · Phase 1, Phase 2 · NCT06147856
Conditions: Phenylketonuria
At a glance
- Research payments reported, 2025
- $37,294
- U.S. investigators named
- 5
- Sites paid
- 5
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-3210 (drug)
- Dates
- Started 2024-03-29; completion 2027-08-05
- Results posted
- Not yet
The main goal of this study is to assess the safety, and tolerability of multiple doses of mRNA-3210 in participants with phenylketonuria (PKU).
From ClinicalTrials.gov, last updated 2024-10-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $37,294 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michele Spencer-manzon, M.D. Medical Genetics · New Haven, CT
- Barbara K. Burton, MD Medical Genetics · Chicago, IL
- Majed J. Dasouki, MD Medical Genetics · Kansas City, MO
- Brian Shayota, M.D., M.P.H. Medical Genetics · Oklahoma City, OK
- Markey C. Mcnutt II, MD Medical Genetics · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $21,949
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $6,750
- University of Utah Hospital and Clinics, UT $5,000
- Ut Southwestern Medical Center $3,262
- Adventhealth Orlando, FL $334
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.